NetworkNewsBreaks – BriaCell Therapeutics Corp.
Post# of 69
(Total Views: 205)
Posted On: 01/02/2019 4:52:52 PM
NetworkNewsBreaks – BriaCell Therapeutics Corp. (OTC: BCTXF) (TSX.V: BCT) Completes Novel Frozen Formulation of Bria-IMT; Announces Participation in Two Upcoming Conferences
BriaCell Therapeutics (OTC: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, today announced multiple updates including completion of its development of a novel frozen formulation of Bria-IMT, its upcoming attendance at the Biotech Showcase taking place Jan. 7-9, 2019 in San Francisco, and the acceptance of an abstract for presentation of advances in Bria-IMT and BriaDX programs at the 2019 Keystone Symposia scientific conference taking place Jan. 20-24, 2019, in Vancouver, British Columbia. According to the update, the new frozen Bria-IMT formulation will provide for on-demand shipment to clinical sites and accommodate higher volumes of patients at reduced costs per-dose.
“Currently, the old formulation of Bria-IMT used in the clinical trials was cumbersome to prepare, as it had to be processed the day before administration to patients,” BriaCell President and CEO Dr. Bill Williams stated in the news release. “This created a great deal of inconvenience and complexities for the manufacturer, clinicians and patients. The new frozen formulation has shown improved potency and stability in vitro and, based on its constituents and injection route, is expected to be highly bioavailable. This enhances Bria-IMT’s potential to address patient needs as a ready-to-use treatment alternative that can be prepared in advance, is easily transportable to distant locations in large quantities, is easy to use, and is safe and highly effective. We are excited to add this novel technology to our growing immunotherapy franchise as we advance safe and effective treatment solutions for advanced breast cancer, an unmet medical need. We look forward to the efficacy data of our ongoing clinical trial, which will provide further evidence for this promising novel therapy to bring hope to patients with advanced breast cancer.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
BriaCell Therapeutics (OTC: BCTXF) (TSX.V: BCT), a biotechnology company developing targeted, safe treatments for cancer, today announced multiple updates including completion of its development of a novel frozen formulation of Bria-IMT, its upcoming attendance at the Biotech Showcase taking place Jan. 7-9, 2019 in San Francisco, and the acceptance of an abstract for presentation of advances in Bria-IMT and BriaDX programs at the 2019 Keystone Symposia scientific conference taking place Jan. 20-24, 2019, in Vancouver, British Columbia. According to the update, the new frozen Bria-IMT formulation will provide for on-demand shipment to clinical sites and accommodate higher volumes of patients at reduced costs per-dose.
“Currently, the old formulation of Bria-IMT used in the clinical trials was cumbersome to prepare, as it had to be processed the day before administration to patients,” BriaCell President and CEO Dr. Bill Williams stated in the news release. “This created a great deal of inconvenience and complexities for the manufacturer, clinicians and patients. The new frozen formulation has shown improved potency and stability in vitro and, based on its constituents and injection route, is expected to be highly bioavailable. This enhances Bria-IMT’s potential to address patient needs as a ready-to-use treatment alternative that can be prepared in advance, is easily transportable to distant locations in large quantities, is easy to use, and is safe and highly effective. We are excited to add this novel technology to our growing immunotherapy franchise as we advance safe and effective treatment solutions for advanced breast cancer, an unmet medical need. We look forward to the efficacy data of our ongoing clinical trial, which will provide further evidence for this promising novel therapy to bring hope to patients with advanced breast cancer.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)